Thomas Glocer - Merck Independent Director
| MRK Stock | EUR 136.80 1.60 1.16% |
Director
Mr. Thomas H. Glocer is Independent Director of the Company.Mr. Glocer has extensive management, operational, technology and international business expertise, including his history of accomplishment and executive ability as CEO and a Director of Thomson Reuters Corporationrationration. In addition, his directorships at other public companies, including his service as Lead Director and as a member of the Operations and Technology Committee at Morgan Stanley, provide him with valuable experience on governance issues facing public companies. He is Retired Chief Executive Officer, Thomson Reuters Corporation since December 2011, prior to which he was Chief Executive Officer of Thomson Reuters from 2008 and Chief Executive Officer of its predecessor, Reuters Group PLC, from 2001. Founder and Managing Partner, Angelic Ventures, L.P Director, Council on Foreign Relations nominated Director, Morgan Stanley Member, Board of Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitors, and Presidents Council on International Activities at Yale University since 2007.
| Age | 59 |
| Tenure | 17 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | DIRECTOR Age | ||
| Wenqi Jiang | Guangzhou Baiyunshan Pharmaceut | 61 | |
| Shou Chao | CanSino Biologics | 56 | |
| Juyan Liu | Guangzhou Baiyunshan Pharmaceut | 59 | |
| Chunbo Zhang | Guangzhou Baiyunshan Pharmaceut | 42 | |
| Xianrong Huang | Guangzhou Baiyunshan Pharmaceut | 57 | |
| Xiaoping Chu | Guangzhou Baiyunshan Pharmaceut | 63 | |
| Hong Li | Guangzhou Baiyunshan Pharmaceut | 56 | |
| Weihong Wang | Guangzhou Baiyunshan Pharmaceut | 56 | |
| Changhai Wu | Guangzhou Baiyunshan Pharmaceut | 57 | |
| Art Garcia | Elanco Animal Health | 58 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Matthias Heinzel, CEO Board | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Gerhard Schmitz, Head Accounting | ||
| Christine Seidman, Independent Director | ||
| Kathy Warden, Independent Director | ||
| Constantin Fest, Head Relations | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Peter Guenter, CEO Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Marcus Kuhnert, CFO Board | ||
| Peter Wendell, Independent Director | ||
| Friederike Rotsch, Group Compliance | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director | ||
| Dirk Toepfer, Chief Officer | ||
| Pamela Craig, Independent Director | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Kai Beckmann, CEO Board | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.36 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 60.26 % | |||
| Price To Earning | 36.46 X | |||
| Price To Book | 2.77 X | |||
| Price To Sales | 3.80 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.